Pacific Biosciences/$PACB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Ticker
$PACB
Sector
Primary listing
Employees
575
Headquarters
Website
PACB Metrics
BasicAdvanced
$529M
-
-$1.71
2.32
-
Price and volume
Market cap
$529M
Beta
2.32
52-week high
$2.37
52-week low
$0.85
Average daily volume
10M
Financial strength
Current ratio
8.692
Quick ratio
7.231
Long term debt to equity
1,939.817
Total debt to equity
1,939.817
Interest coverage (TTM)
-27.70%
Profitability
EBITDA (TTM)
-200.053
Gross margin (TTM)
32.58%
Net profit margin (TTM)
-325.80%
Operating margin (TTM)
-142.82%
Effective tax rate (TTM)
-0.09%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-12.25%
Return on equity (TTM)
-205.90%
Valuation
Price to revenue (TTM)
3.361
Price to book
14.67
Price to tangible book (TTM)
-1.78
Growth
Revenue change (TTM)
-10.72%
Earnings per share change (TTM)
16.90%
3-year revenue growth (CAGR)
4.11%
10-year revenue growth (CAGR)
7.73%
3-year earnings per share growth (CAGR)
8.13%
10-year earnings per share growth (CAGR)
9.87%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Bulls say / Bears say
PacBio is growing its share of the long-read sequencing market in China by strengthening and expanding its distribution agreement with Haorui Gene amid an import ban on Illumina sequencers, positioning itself as a key supplier to clinical and research labs throughout the region. (FierceBiotech)
PacBio signed a partnership with Roche Diagnostics to co-develop clinical in-vitro diagnostic products, receiving $35 million upfront and up to $40 million in milestone payments, which bolsters its clinical commercial strategy and diversifies its revenue base. (DrugDiscoveryNews)
A study covered by RTTNews in the American Journal of Human Genetics reported PacBio’s HiFi sequencing achieved a 93% diagnostic rate in 100 challenging rare disease cases, demonstrating its technical edge and potential to streamline and consolidate multiple diagnostic workflows. (Nasdaq)
PacBio is set to cut around 120 jobs and reduce annual adjusted operating expenses by $45–$50 million due to NIH funding reductions and new tariffs, highlighting significant short-term cost challenges even though revenue guidance remains unchanged. (Reuters)
Uncertainty surrounding funding in U.S. academia and changes in NIH policies have eroded investor confidence and led to a steep drop in sales of high-priced instruments, forcing PacBio to make layoffs and implement widespread cost cuts. (Barron's)
First quarter 2025 revenue from the Americas declined by 8% compared to the prior year, underscoring how instrument placements are highly sensitive to changes in academic and government research funding. (Barron's)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pacific Biosciences stock?
Pacific Biosciences (PACB) has a market cap of $529M as of November 09, 2025.
What is the P/E ratio for Pacific Biosciences stock?
The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of November 09, 2025.
Does Pacific Biosciences stock pay dividends?
No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Pacific Biosciences dividend payment date?
Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacific Biosciences?
Pacific Biosciences (PACB) has a beta rating of 2.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.